Study on role of C-reactive protein as a prognostic marker in diabetic and non-diabetic patients with acute myocardial infarction
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 8, Pages 888-897
AbstractLimited data is available about C Reactive protein (CRP) and its significance in mortality and morbidity in Acute Myocardial infarction (AMI) in diabetic patients. The aim of current study is to examine whether CRP levels are associated with for long-term all-cause, cardiovascular, and cardiac mortality in AMI patients with diabetes and those without separately.
Methods: This is a cohort study on 100 patients with Acute Myocardial Infarction out of which 50% are diabetics and 50% are non-diabetics.
Results: The CRP level cut off was taken as 7 mg/L in our study. The patients were divided into two groups, Diabetics and Non Diabetics. In diabetic patients with AMI, 96% of patients have crp levels more than 7 mg/L. In non-diabetic patients with AMI, 88% of patients have crp level more than 7mg/L. The mean CRP in diabetic group was 51.80 mg/l as compared to 15.78mg/l in non-diabetic group which was statistically significant (p<0.001). Diabetic patients who died in hospital presented with higher plasma levels of CRP on admission as compared to non-diabetic patients.
Thus, this study reveals that CRP can be used as a prognostic marker in diabetic patients with AMI.
Conclusion: In diabetic patients with AMI CRP levels are higher on admission, CRP value is an independent predictor of long term, all cause, cardiovascular and cardiac mortality after AMI.
- Article View: 21
- PDF Download: 50